Printer Friendly

CELLEX BIOSCIENCES, INC. RECEIVES $500,000 GOVERNMENT GRANT FOR FURTHER DEVELOPMENT OF ITS OXYCELL BIOREACTOR

 MINNEAPOLIS, June 10 /PRNewswire/ -- Cellex Biosciences, Inc. (NASDAQ: CLXX) announced today that it has been awarded a two-year, $500,000 Phase II Small Business Innovation Research ("SBIR") grant from the National Cancer Institute of the National Institutes of Health, to fund the development and adaptation of the Cellex patented OXYCELL(TM) bioreactor for incorporation into the company's commercial scale ACUSYST(TM) system for multi-kilogram protein production. The OXYCELL bioreactor is currently patented in the United States, Canada and Europe and has patent applications pending worldwide.
 Richard E. Sakowicz, Cellex Biosciences, Inc. president and chief operating officer, said, "Receiving this SBIR award points out the significance and novelty of the OXYCELL cell culture technology. We are extremely pleased that the National Cancer Institute has found our technology so significant as to fund its continued development."
 SBIR grants support the development of technology in businesses with less than 500 employees. The award of the Phase II grant follows the successful completion of feasibility studies conducted by Cellex under a previously awarded Phase I SBIR grant. Phase I projects showing the most promise are eligible to compete for Phase II funding up to a maximum of $500,000 for continued development leading to commercialization of products.
 Cellex Biosciences, Inc., headquartered in Minneapolis, is dedicated to providing cell processing products and services to meet the needs of human health care and biotechnology markets worldwide.
 -0- 6/10/93
 /CONTACT: Yvonne L. Marschner-Bova, director, Investor Relations, Cellex Biosciences, Inc., 313-871-7350 or (fax) 313-873-4935/
 (CLXX)


CO: Cellex Biosciences, Inc.; National Cancer Institute ST: Minnesota IN: MTC SU:

SM -- DE003 -- 0486 06/10/93 09:22 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 10, 1993
Words:270
Previous Article:AIRBUS INDUSTRIE LAUNCHES THE A319
Next Article:ODETICS DELIVERS CART MACHINE TO PORTUGAL'S TVI
Topics:


Related Articles
CELLEX BIOSCIENCES ANNOUNCES AGREEMENT TO JOIN FORCES WITH LSL GROUP, LTD.
CELLEX BIOSCIENCES, INC. REPORTS FIRST QUARTER RESULTS
CELLEX BIOSCIENCES RECEIVES U.S. PATENT ON CELL CULTURE APPARATUS
Cellex Biosciences Announces a Profitable Fourth Quarter Record Revenues and Significantly Reduced Losses for Fiscal Year
CELLEX BIOSCIENCES Announces First Quarter Results
Cellex Biosciences, Inc. Reports Second Quarter Results
CELLEX BIOSCIENCES Reports First Quarter Results
CELLEX BIOSCIENCES Announces Proposed Recapitalization Plan
Cellex Biosciences Reports Third Quarter Results, Status of Recapitalization Plan

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters